Previous 10 | Next 10 |
2023-10-27 16:13:47 ET Summary Ironwood Pharmaceuticals, Inc. is a Boston-based drug company focused on developing treatments for gastrointestinal disorders. The company's revenue-generating product is Linzess, which is approved for multiple GI indications. Ironwood recently a...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its third quarter 2023 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 9, 2023. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. and Canada)...
– Data reinforce the impact of linaclotide on symptoms of IBS-C and CIC – – Additional studies highlight the burden of these disorders on patients – Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a global GI-focused healthcare company, present...
– Data show approximately 50% reduction of parenteral support (PS) volume – – 100% of patients were clinical responders – – 78% of patients achieved one or more days off PS – – Results support apraglutide as a potentiall...
– Data demonstrates that linaclotide reduces the need for rescue medications in this patient population – – Additional presentations further characterize the efficacy and safety profiles of linaclotide as the only FDA-approved prescription therapy for this patient pop...
2023-09-28 12:52:41 ET More on Ironwood Pharmaceuticals Ironwood: Pipeline Progresses As FDA Approves LINZESS Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Ironwood Pharmaceuticals Historical ear...
2023-09-19 11:18:41 ET More on Ironwood Pharmaceuticals Ironwood: Pipeline Progresses As FDA Approves LINZESS Seeking Alpha's Quant Rating on Ironwood Pharmaceuticals Historical earnings data for Ironwood Pharmaceuticals Financial information for Ironwood Pha...
2023-08-08 11:26:07 ET Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2023 Earnings Call Transcript August 08, 2023 08:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Sravan Emany - Chief Financial Office...
2023-08-08 07:25:44 ET Ironwood Pharmaceuticals press release ( NASDAQ: IRWD ): Q2 Non-GAAP EPS of -$6.71 misses by $6.96 . Revenue of $107.38M (+10.4% Y/Y) beats by $3.66M . Ironwood is increasing its 2023 U.S. LINZESS net sales and total revenue growth guidan...
– LINZESS (Iinaclotide) EUTRx prescription demand growth increased 9% year-over-year; LINZESS U.S. net sales of $270 million, an increase of 9% year-over-year – – Expands clinical utility of LINZESS with FDA approval for pediatric patients ages 6-17 years-old sufferin...
News, Short Squeeze, Breakout and More Instantly...
Ironwood Pharmaceuticals Inc. Company Name:
IRWD Stock Symbol:
NASDAQ Market:
Ironwood Pharmaceuticals Inc. Website:
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of I...
2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for IRWD on May 22, 2024 05:13AM ET. The previous analyst recommendation was Overweight. IRWD was trading at $6.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-05-22 07:00:07 ET Mohit Bansal from Wells Fargo issued a price target of $14.00 for IRWD on 2024-05-22 05:13:00. The adjusted price target was set to $14.00. At the time of the announcement, IRWD was trading at $6.78. The overall price target consensus is at $16.00 ...